Table 5 cART-experienced and cART-naïve RPV/TDF/FTC patients who discontinued treatment between April 2014 and October 2015; reasons for discontinuation and next cART regimen
From: Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study
Number (%) of patients | ||
|---|---|---|
cART-naïve RPV/TDF/FTC (n = 48) | cART-experienced RPV/TDF/FTC (n = 596) | |
Number of patients discontinuating | 7 (14.5%) | 159 (26.7%) |
Reasons for discontinuation | ||
Treatment failure | 1 (2.1%) | 5 (0.8%) |
Physician decision | 2 (4.2%) | 34 (5.7%) |
Patient request | 1 (2.1%) | 11 (1.8%) |
CNS toxicity | 0 (0%) | 10 (1.7%) |
Availability of more effective treatment | 1 (2.1%) | 7 (1.2%) |
Kidney toxicity | 0 (0%) | 7 (1.2%) |
Other toxicities (including gastrointestinal, liver, endocrine, dyslipidemia, abnormal fat distribution) | 0 (0%) | 8 (1.3%) |
Other causes (pregnancy, enrolment in drug trial, drug interaction, prevention of side-effects, non-compliance) | 0 (0%) | 8 (1.3%) |
Unspecified causes | 0 (0%) | 9 (1.5%) |
Unknown | 2 (4.2%) | 60 (10.1%) |
Next treatment regimen after discontinuation | ||
INSTI-based | ||
DTG/ABC/3TC co-formulation | 2 (4.2%) | 25 (4.2%) |
EGV/COB/TDF/FTC co-formulation | 2 (4.2%) | 16 (2.7%) |
Other DTG-based regimen | 1 (2.1%) | 29 (4.9%) |
Other EVG-based regimen | 0 (0%) | 3 (0.5%) |
RAL-based regimen | 1 (1.2%) | 13 (2.2%) |
PI-based | 0 (0%) | 18 (3.0%) |
NNRTI-based | 0 (0%) | 24 (4.0%) |
Other | 0 (0%) | 4 (0.7%) |
Unknown | 1 (1.2%) | 27 (4.5%) |